454 related articles for article (PubMed ID: 30280368)
1. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
Liu X; Li X; Li X; Li Z; Zhao D; Liu S; Zhang M; Zhang F; Zhu P; Chen J; Wei W; Lin B; Zhou Y; Chen J; Pang Y; Zhang L; Sun X; Yu Z; Jia Y; Wang J; Sun W; Chiu F; Pang L; Wang G
Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
[TBL] [Abstract][Full Text] [Related]
2. Clinical and immunological consequences of total glucosides of paeony treatment in Sjögren's syndrome: A randomized controlled pilot trial.
Zhou Y; Jin L; Kong F; Zhang H; Fang X; Chen Z; Wang G; Li X; Li X
Int Immunopharmacol; 2016 Oct; 39():314-319. PubMed ID: 27517517
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
Shao Q; Wang S; Jiang H; Liu L
Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847
[No Abstract] [Full Text] [Related]
4. Combined use of total glucosides of paeony and hydroxychloroquine in primary Sjögren's syndrome: A systematic review.
Zhang A; Chen S; Lin R
Immun Inflamm Dis; 2023 Oct; 11(10):e1044. PubMed ID: 37904705
[TBL] [Abstract][Full Text] [Related]
5. Traditional Chinese medicine compound ShengJinRunZaoYangXue granules for treatment of primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled clinical trial.
Hu W; Qian X; Guo F; Zhang M; Lyu C; Tao J; Gao Z; Zhou Z
Chin Med J (Engl); 2014; 127(15):2721-6. PubMed ID: 25146603
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.
Mariette X; Seror R; Quartuccio L; Baron G; Salvin S; Fabris M; Desmoulins F; Nocturne G; Ravaud P; De Vita S
Ann Rheum Dis; 2015 Mar; 74(3):526-31. PubMed ID: 24347569
[TBL] [Abstract][Full Text] [Related]
7. The Effectiveness and Safety of Total Glucosides of Paeony in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.
Feng Z; Zhang BQ; Zhu YM; Yu BB; Fu L; Zhou LL; Zhou XP; Lu Y
Front Pharmacol; 2019; 10():550. PubMed ID: 31178729
[No Abstract] [Full Text] [Related]
8. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
Mariette X; Ravaud P; Steinfeld S; Baron G; Goetz J; Hachulla E; Combe B; Puéchal X; Pennec Y; Sauvezie B; Perdriger A; Hayem G; Janin A; Sibilia J
Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of the efficacy and safety of herbal decoction CheReCunJin alone and combined with hydroxychloroquine for treating primary Sjögren's syndrome: A randomized controlled trial.
Shao Q; Jin L; Li C; Wang J; Wang M; Wang Q; Wu B
Explore (NY); 2022; 18(4):416-422. PubMed ID: 34417112
[TBL] [Abstract][Full Text] [Related]
11. Effects of total glucosides of peony on AQP-5 and its mRNA expression in submandibular glands of NOD mice with Sjogren's syndrome.
Wu GL; Pu XH; Yu GY; Li TY
Eur Rev Med Pharmacol Sci; 2015 Jan; 19(1):173-8. PubMed ID: 25635992
[TBL] [Abstract][Full Text] [Related]
12. [Clinical observation on effect of total glucosides of paeony in treating patients with non-systemic involved Sjögren syndrome].
Zhang HF; Hou P; Xiao WG
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Jul; 27(7):596-8. PubMed ID: 17717915
[TBL] [Abstract][Full Text] [Related]
13. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.
Khurshudian AV
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jan; 95(1):38-44. PubMed ID: 12539025
[TBL] [Abstract][Full Text] [Related]
14. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
Dörner T; Posch MG; Li Y; Petricoul O; Cabanski M; Milojevic JM; Kamphausen E; Valentin MA; Simonett C; Mooney L; Hüser A; Gram H; Wagner FD; Oliver SJ
Ann Rheum Dis; 2019 May; 78(5):641-647. PubMed ID: 30826774
[TBL] [Abstract][Full Text] [Related]
15. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.
Bowman SJ; Everett CC; O'Dwyer JL; Emery P; Pitzalis C; Ng WF; Pease CT; Price EJ; Sutcliffe N; Gendi NST; Hall FC; Ruddock SP; Fernandez C; Reynolds C; Hulme CT; Davies KA; Edwards CJ; Lanyon PC; Moots RJ; Roussou E; Giles IP; Sharples LD; Bombardieri M
Arthritis Rheumatol; 2017 Jul; 69(7):1440-1450. PubMed ID: 28296257
[TBL] [Abstract][Full Text] [Related]
16. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
[TBL] [Abstract][Full Text] [Related]
17. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
Juarez M; Diaz N; Johnston GI; Nayar S; Payne A; Helmer E; Cain D; Williams P; Devauchelle-Pensec V; Fisher BA; Giacomelli R; Gottenberg JE; Guggino G; Kvarnström M; Mariette X; Ng WF; Rosas J; Sánchez Bursón J; Triolo G; Barone F; Bowman SJ
Rheumatology (Oxford); 2021 Mar; 60(3):1364-1375. PubMed ID: 32949140
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
Baer AN; Gottenberg JE; St Clair EW; Sumida T; Takeuchi T; Seror R; Foulks G; Nys M; Mukherjee S; Wong R; Ray N; Bootsma H
Ann Rheum Dis; 2021 Mar; 80(3):339-348. PubMed ID: 33168545
[TBL] [Abstract][Full Text] [Related]
20. ESSPRI and other patient-reported indices in patients with primary Sjogren's syndrome during 100 consecutive outpatient visits at one rheumatological clinic.
Pertovaara M; Korpela M
Rheumatology (Oxford); 2014 May; 53(5):927-31. PubMed ID: 24464708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
